araag2/HINT huggingface dataset:
Clinical trial NCT00431795 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pegylated liposomal doxorubicin (caelyx), epirubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-75 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate bone marrow function (Absolute neutrophil count >1000/mm^3, Platelet
             count>100000/mm^3, Hemoglobin>9gr/mm^3)

          -  Histologically- or cytologically- confirmed breast adenocarcinoma

          -  No prior anthracycline-based chemotherapy as treatment of advanced breast cancer

          -  No prior chemotherapy with ≥ 300mg/m2 doxorubicin or ≥ 540mg/m2 epirubicin as adjuvant
             setting

          -  At least 4 weeks interval since prior anticancer treatment

          -  Measurable disease as defined by the presence of at least one measurable lesion(except
             bone metastases, ascites or pleural effusions)

          -  Life expectancy > 3 months

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Documented history of congestive heart failure (CHF), serious arrhythmia, or
             myocardial infarction (within 6 months)

          -  Other invasive malignancy except nonmelanoma skin cancer or acute infection.

          -  Radiation of measurable disease (except brain metastases)

          -  Progressive brain metastases according to clinical or radiological criteria.

          -  Brain metastases without prior radiation therapy
Clinical trial NCT01203072 (phase 2, status: completed)
Conditions: venous thromboembolism, deep vein thrombosis, total knee arthroplasty
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219, I82.491, I82.492, I82.493, I82.499, I82.591, I82.592, I82.593
Drugs: du-176b, du-176b, du-176b, du-176b, placebo
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing unilateral total knee arthroplasty

        Exclusion Criteria:

          -  risks of hemorrhage

          -  thromboembolic risks

          -  weight less than 40 kg

          -  pregnant, suspect pregnancy, or subjects who want to become pregnant
Clinical trial NCT00372385 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: ribavirin, pegylated interferon alfa 2a, placebo, telaprevir
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA

          -  Have been infected with Hepatitis C virus for greater than (>) 6 months

          -  Seronegative for hepatitis B surface antigen and human immunodeficiency virus 1 and 2

          -  Must agree to use 2 methods of contraception, including 1 barrier method, during and
             for 24 weeks after the completion of the study (unless the subject is a female of
             documented non-child-bearing potential)

          -  Female subjects must have a negative pregnancy test at all visits before the first
             dose.

        Exclusion Criteria:

          -  Received any approved or investigational drug or drug regimen for the treatment of
             hepatitis C.

          -  Any medical contraindications to Peg-IFN-alfa-2a or Ribavirin therapy

          -  Any other cause of significant liver disease in addition to hepatitis C; this may
             include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis,
             autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis
             or primary biliary cirrhosis.

          -  Diagnosed or suspected hepatocellular carcinoma.

          -  Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a
             liver biopsy taken within 2 years before Study start.

          -  Alcohol/drug abuse or excessive use in the last 12 months.

          -  Participation in any investigational drug study within 90 days before drug
             administration or participation in more than 2 drug studies in the last 12 months
             (exclusive of the current study).
Clinical trial NCT00296400 (phase 2, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: rosuvastatin, atorvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  greater than or equal to 18 years of age

          -  Hyperlipidemia

          -  Urinary protein

        Exclusion Criteria:

          -  Previous rosuvastatin treatment < 6 months prior to Visit 1

          -  Statin intolerance

          -  Severe hypertension

          -  Diabetes
Clinical trial NCT01263496 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin, alogliptin, alogliptin, alogliptin, voglibose
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Had completed the phase 2 dose-ranging study (i.e., the subject had completed the
             study visit at Week 12).

        Exclusion Criteria:

          -  Had clinical manifestations of hepatic impairment (e.g., an aspartate aminotransferase
             or alanine aminotransferase value 2.5 times or more of the upper reference limit at
             Week 8 of treatment in the phase 2 dose-ranging study).

          -  Had clinical manifestations of renal impairment (e.g., a creatinine value of 2 mg/dL
             or more at Week 8 of treatment in the phase 2 dose-ranging study).
Clinical trial NCT01475253 (phase 2, status: terminated)
Conditions: interstitial cystitis
ICD codes: N30.10, N30.11
Drugs: lidocaine releasing intravesical system - liris®
SMILES: OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
Reason stopped: 
    this study was not enrolled completely and was terminated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women age 18 and over

          -  Diagnosed with Interstitial Cystitis as defined by protocol

          -  Able and willing to complete questionnaires and diary

          -  Able to comply with visit schedule including Day 14 Removal visit

          -  Completion of blinded study prior to enrolling in unblinded part of study

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Bladder or urethra anatomical feature that would prevent the safe indwelling or
             insertion of the investigational product

          -  History or presence of any condition that would make it difficult to evaluate symptoms

          -  Did not complete blinded study (unblinded part of study only)
Clinical trial NCT00098670 (phase 2, status: completed)
Conditions: b-cell chronic lymphocytic leukemia, stage i chronic lymphocytic leukemia, stage ii chronic lymphocytic leukemia, stage iii chronic lymphocytic leukemia, stage iv chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10, C91.11, C91.12, C91.10, C91.11, C91.12, C91.10, C91.11, C91.12, C91.10, C91.11, C91.12, C91.10
Drugs: fludarabine phosphate
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Specific Diagnosis of B-Cell CLL

          -  An absolute lymphocytosis of > 5,000/μL

          -  Morphologically, the lymphocytes must appear mature with < 55% prolymphocytes

          -  Bone marrow examination must include at least a unilateral aspirate and biopsy; the
             aspirate smear must show > 30% of all nucleated cells to be lymphoid or the bone
             marrow core biopsy must show lymphoid infiltrates compatible with marrow involvement
             by CLL; the overall cellularity must be normocellular or hypercellular

          -  Local institution lymphocyte phenotype must reveal a predominant B-cell monoclonal
             population sharing a B-cell marker (CD19, CD20, CD23) with the CD5 antigen, in the
             absence of other pan-T-cell markers; additionally, the B-cells must be monoclonal with
             regard to expression of either κ or λ and have surface immunoglobulin expression of
             low density; patients with bright surface immunoglobulin levels must have CD23
             co-expression

          -  Patients must be in the intermediate- or high-risk categories of the modified
             three-stage Rai staging system (i.e., stages I, II, III, or IV)

          -  Patients in the intermediate-risk group must have evidence of active disease as
             demonstrated by at least one of the following criteria:

               -  Massive or progressive splenomegaly, hepatomegaly and/or lymphadenopathy;

               -  Presence of weight loss > 10% over the preceding 6 month period;

               -  Grade 2 or 3 fatigue;

               -  Fevers > 100.5°F or night sweats for greater than 2 weeks without evidence of
                  infection;

               -  Progressive lymphocytosis with an increase of > 50% over a 2 month period or an
                  anticipated doubling time of less than 6 months

          -  No prior therapy for CLL including corticosteroids for autoimmune complications that
             have developed since the initial diagnosis of CLL

          -  No medical condition requiring chronic use of oral corticosteroids

          -  Performance Status 0 - 2

          -  Due to alterations in host immunity, patients with HIV may not be enrolled

          -  Due to the unknown teratogenic potential of alemtuzumab, pregnant or nursing women may
             not be enrolled; women and men of reproductive potential should agree to use an
             effective means of birth control

          -  Creatinine =< 1.5 x upper limit of institutional normal value

          -  Coomb's Testing NEGATIVE
Clinical trial NCT00529542 (phase 2, status: completed)
Conditions: polycystic ovary syndrome
ICD codes: E28.2, Q61.3, Q61.2, Q61.19, Z82.71
Drugs: lipitor, placebo
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: Women with PCOS

          -  8 or fewer menstrual periods per year

          -  elevated serum total testosterone

          -  elevated LDL cholesterol

        Exclusion Criteria:

          -  current pregnancy or breastfeeding

          -  current use of oral contraceptives, progestins

          -  insulin sensitizing medications

          -  thyroid disease, hyperprolactinemia, active liver disease, type 1 or type 2 diabetes
Clinical trial NCT00229723 (phase 2, status: completed)
Conditions: neoplasms, squamous cell
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: gefitinib (iressa), cisplatin, gefitinib (iressa)
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed stage III or IVA squamous cell carcinoma of
             the head and neck

          -  No prior surgery or chemotherapy/biological therapy/radiation therapy

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)

          -  Life expectancy of more than 12 weeks

        Exclusion Criteria:

          -  Cancers of the nasal space, oral cavity and larynx; or certain lung diseases.

          -  Abnormal blood chemistry; uncontrolled respiratory, cardiac, hepatic, or renal
             disease; or coexisting malignancies.
Clinical trial NCT01065077 (phase 2, status: terminated)
Conditions: acute heart failure
ICD codes: I50.811, I50.21, I50.31, I50.813, I50.23, I50.33, I50.41
Drugs: cinaciguat (bay58-2667), cinaciguat (bay58-2667), cinaciguat (bay58-2667), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or
             women without childbearing potential defined as postmenopausal women aged 55 years or
             older, women with bilateral tubal ligation, women with bilateral ovariectomy, and
             women with a hysterectomy

          -  Subjects must have the clinical diagnosis of CHF made at least three months prior to
             enrollment

          -  Subjects must experience worsening of both of the symptoms below leading to
             hospitalization at the time of entry into the study:

               -  dyspnea and

               -  clinical evidence of volume overload

        Exclusion Criteria:

          -  Acute de-novo heart failure

          -  Acute myocardial infarction and/or myocardial infarction within 30 days

          -  Valvular heart disease requiring surgical intervention during the course of the study

          -  Heart failure due to or associated with uncorrected primary valvular disease,
             malfunctioning artificial heart valve, or uncorrected congenital heart disease

          -  Primary hypertrophic cardiomyopathy

          -  Acute inflammatory heart disease, eg, acute myocarditis

          -  Unstable angina requiring angiography
Clinical trial NCT01234857 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ridaforolimus + dalotuzumab, exemestane, ridaforolimus, dalotuzumab
SMILES: CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O
Eligibility criteria:

        Inclusion Criteria The prospective participant must meet, at least, all of the criteria
        below to be eligible for study participation.

        The participant:

          -  Has a confirmed diagnosis of breast cancer that is metastatic or locally advanced and
             is estrogen receptor positive and human epidermal growth factor receptor 2 (HER-2)
             negative ;

          -  Is post-menopausal;

          -  Is at least 18 years of age;

          -  Has a life expectancy of at least 3 months;

          -  Has had a recurrence or progression of cancer after prior treatment and patient has
             received at least one line of endocrine therapy for metastatic disease, OR the
             patient's cancer has recurred within 6 months after the last dose of anastrozole or
             letrozole;

          -  Has an available archival tumor specimen;

          -  Has voluntarily agreed to participate by signing informed consent.

        Exclusion Criteria If the prospective participant meets any of the criteria below (among
        others determined by the study staff) they will NOT be eligible for study participation.

        The participant:

          -  Is receiving any other systemic tumor therapy;

          -  Has previously received rapamycin or rapamycin analogs;

          -  Has received prior treatment with insulin-like growth factor 1 receptor (IGF-1R)
             inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, or other experimental agents
             that target the PI3K, protein kinase B (AKT), or mammalian target of rapamycin (mTOR)
             pathways;

          -  Has known allergy to macrolide antibiotics;

          -  Has an active infection that requires antibiotics;

          -  Has significant or uncontrolled cardiovascular disease;

          -  Has poorly controlled Type 1 or 2 diabetes mellitus;

          -  Is known to be human immunodeficiency virus (HIV) positive;

          -  Has a known history of active Hepatitis B or C.
Clinical trial NCT00426283 (phase 2, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: flovent
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent for study by subject, or parent/guardian if subject is a
             minor. Assent will be obtained from all minors 11 years of age and older.

          -  Histological findings on esophageal biopsy to include peak eosinophil density ≥ 24 per
             high power field (400x) in the proximal or distal esophagus validated by a pathologist
             at CCHMC.

          -  Allergy evaluation including skin-prick testing with multiple food antigens to ensure
             elimination diet is not indicated.

          -  Have undergone a minimum 3 months of elimination diet as indicated by skin-prick
             testing without detectable resolution by repeat endoscopy with biopsies demonstrating
             persistent EE OR subject/parental refusal to follow elimination diet. If the
             subject/parent refuses the elimination diet, they are eligible for this study.

          -  Treatment with a proton-pump inhibitor for at least two months (rounded to nearest
             month) prior to endoscopy OR failure of histological improvement as defined by < 1
             eosinophil per HPF after 2 month (rounded to nearest month) trial of proton pump
             inhibitor documented by prior endoscopy. The PPI must be used prior to endoscopy to
             rule out the possibility of GERD.

        Exclusion Criteria:

          -  History of poor tolerance to Fluticasone Propionate (FP), as defined as multiple
             episodes of oral candidiasis, hypothalamic-pituitary-adrenal axis suppression as
             evidenced by signs of Cushing syndrome, headaches, or increased respiratory infections
             during exposure to Flovent

          -  Unable to cooperate with use of MDI

          -  Pregnant females

          -  Concurrent or recent (within 3 months) use of systemic corticosteroids.

          -  Unable to swallow medicines (i.e., fed only by gastrostomy tube).

          -  Comorbid eosinophilic disorders.

          -  Previously treated with swallowed glucocorticoid for EE within 3 months of the
             screening visit. Nasal glucocorticoids taken for EE are permitted.
Clinical trial NCT00106262 (phase 2, status: terminated)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: velcade (bortezomib), irinotecan
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

          -  Female subject is either post-menopausal or surgically sterilized or willing to use an
             acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
             duration of the study.

          -  age > 18

          -  Karnofsky performance status > 60%

          -  Measurable disease on clinical exam or by RECIST criteria

          -  One prior platinum-based systemic chemotherapy regimen for advanced disease is allowed
             but not required. Chemotherapy administered as a radiosensitizer in conjunction with
             primary radiotherapy is not considered a systemic chemotherapy regimen and is also
             allowed. Patients eligible for a higher priority study will be excluded.

          -  Life expectancy > 6 weeks

          -  Peripheral neuropathy ≤ Grade 2 by CTC 3.0 criteria

          -  Women of child-bearing potential must have a negative pregnancy test

          -  Adequate hematopoietic function defined as: ANC ≥ 1500/mm3; Platelets ≥ 100,000/mm3;
             Hemoglobin ≥ 8 g/dL.

          -  Adequate renal and hepatic function defined as: Bilirubin ≤ 1.5 times upper limit of
             normal (ULN); SGOT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 2.5 times ULN; Creatinine ≤
             2 times ULN.

        Exclusion Criteria

          -  Patient has hypersensitivity to bortezomib, boron or mannitol.

          -  Female subject is pregnant or breast-feeding.

          -  Patient has received other investigational drugs with 14 days before enrollment

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Prior treatment with CAMPTOSAR or VELCADE

          -  More than one prior treatment for metastatic disease.

          -  Concurrent uncontrolled illness

          -  Ongoing or active infection

          -  History or active secondary cancer within the last 5 years, except for superficial
             basal cell skin cancers

          -  Psychiatric illness or social situation that would preclude study compliance.